Cargando…

Incidence of solid tumors in polycythemia vera treated with phlebotomy with or without hydroxyurea: ECLAP follow-up data

Detalles Bibliográficos
Autores principales:	Ghirardi, Arianna, Carobbio, Alessandra, Masciulli, Arianna, Barbui, Tiziano
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Nature Publishing Group UK 2018
Materias:	Correspondence
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5802556/ https://www.ncbi.nlm.nih.gov/pubmed/29335456 http://dx.doi.org/10.1038/s41408-017-0038-3

Ejemplares similares

Different effect of hydroxyurea and phlebotomy on prevention of arterial and venous thrombosis in Polycythemia Vera
por: Barbui, Tiziano, et al.
Publicado: (2018)

Clinical outcomes under hydroxyurea treatment in polycythemia vera: a systematic review and meta-analysis
por: Ferrari, Alberto, et al.
Publicado: (2019)

Neutrophil-to-lymphocyte ratio is a novel predictor of venous thrombosis in polycythemia vera
por: Carobbio, Alessandra, et al.
Publicado: (2022)

Indications and use of therapeutic phlebotomy in polycythemia vera: which role for erythrocytapheresis?
por: Teofili, Luciana, et al.
Publicado: (2018)

The CYTO-PV: A Large-Scale Trial Testing the Intensity of CYTOreductive Therapy to Prevent Cardiovascular Events in Patients with Polycythemia Vera
por: Marchioli, Roberto, et al.
Publicado: (2011)

The development of polycythemia vera after phlebotomy treatment for hereditary haemochromatosis
por: van Bommel, Erik JM, et al.
Publicado: (2021)

Hydroxyurea prevents arterial and late venous thrombotic recurrences in patients with myeloproliferative neoplasms but fails in the splanchnic venous district. Pooled analysis of 1500 cases
por: De Stefano, Valerio, et al.
Publicado: (2018)

Optimized and Personalized Phlebotomy Schedules for Patients Suffering From Polycythemia Vera
por: Lilienthal, Patrick, et al.
Publicado: (2020)

Polycythemia vera treatment algorithm 2018
por: Tefferi, Ayalew, et al.
Publicado: (2018)

Genomic characterization of patients with polycythemia vera developing resistance to hydroxyurea
por: Alvarez-Larrán, Alberto, et al.
Publicado: (2020)

Low-risk polycythemia vera treated with phlebotomies: clinical characteristics, hematologic control and complications in 453 patients from the Spanish Registry of Polycythemia Vera
por: Triguero, Ana, et al.
Publicado: (2022)

Polycythemia vera: historical oversights, diagnostic details, and therapeutic views
por: Tefferi, Ayalew, et al.
Publicado: (2021)

Identifying Patients with Polycythemia Vera at Risk of Thrombosis after Hydroxyurea Initiation: The Polycythemia Vera—Advanced Integrated Models (PV-AIM) Project
por: Verstovsek, Srdan, et al.
Publicado: (2023)

Response to: Ruxolitinib withdrawal due to the COVID-19
por: Barbui, Tiziano, et al.
Publicado: (2021)

Treatment of hydroxyurea-resistant/intolerant polycythemia vera: a discussion of best practices
por: Kuykendall, Andrew T.
Publicado: (2023)

Health Care Costs and Thromboembolic Events in Hydroxyurea-Treated Patients with Polycythemia Vera
por: Parasuraman, Shreekant V., et al.
Publicado: (2018)

A randomized phase 3 trial of interferon-α vs hydroxyurea in polycythemia vera and essential thrombocythemia
por: Mascarenhas, John, et al.
Publicado: (2022)

An agenda for future research projects in polycythemia vera and essential thrombocythemia
por: Barbui, Tiziano, et al.
Publicado: (2020)

Increased risk of thrombosis in JAK2 V617F-positive patients with primary myelofibrosis and interaction of the mutation with the IPSS score
por: Barbui, Tiziano, et al.
Publicado: (2022)

Oral hyperpigmentation associated with hydroxyurea in a patient with polycythemia vera: A case report
por: Alshammasi, Baneen, et al.
Publicado: (2020)

Correction to: Treatment of hydroxyurea-resistant/intolerant polycythemia vera: a discussion of best practices
por: Kuykendall, Andrew T.
Publicado: (2023)

Myeloid Sarcoma Developing in Prexisting Hydroxyurea-Induced Leg Ulcer in a Polycythemia Vera Patient
por: Nafil, Hatim, et al.
Publicado: (2013)

Phenotypical differences and thrombosis rates in secondary erythrocytosis versus polycythemia vera
por: Nguyen, Eliane, et al.
Publicado: (2021)

P1041: LEUKOCYTOSIS SELECTS A SUBGROUP OF LOW-RISK PV PATIENTS IN WHOM PHLEBOTOMY-ALONE MAY BE INSUFFICIENT
por: Carobbio, Alessandra, et al.
Publicado: (2023)

Gender effect on phenotype and genotype in patients with post-polycythemia vera and post-essential thrombocythemia myelofibrosis: results from the MYSEC project
por: Barraco, Daniela, et al.
Publicado: (2018)

Driver mutations (JAK2V617F, MPLW515L/K or CALR), pentraxin-3 and C-reactive protein in essential thrombocythemia and polycythemia vera
por: Lussana, Federico, et al.
Publicado: (2017)

Targeting myeloid cells to prevent recurrent stroke in general population: the lesson of hydroxyurea in myeloproliferative neoplasms
por: Barbui, Tiziano, et al.
Publicado: (2018)

A phase 2 study of ruxolitinib, an oral JAK1 and JAK2 inhibitor, in patients with advanced polycythemia vera who are refractory or intolerant to hydroxyurea
por: Verstovsek, Srdan, et al.
Publicado: (2014)

Generalized Chorea Due to Secondary Polycythemia Responding to Phlebotomy
por: Cherian, Ajith, et al.
Publicado: (2021)

Patterns of Hydroxyurea Prescription and Use in Routine Clinical Management of Polycythemia Vera: A Multicenter Chart Review Study
por: Büyükaşık, Yahya, et al.
Publicado: (2020)

Survival and prognosis among 1545 patients with contemporary polycythemia vera: an international study
por: Tefferi, A, et al.
Publicado: (2013)

Treatment Patterns and Blood Counts in Patients With Polycythemia Vera Treated With Hydroxyurea in the United States: An Analysis From the REVEAL Study
por: Grunwald, Michael R., et al.
Publicado: (2020)

Cerebral venous sinus thrombosis in polycythemia vera patients with JAK2V617F mutation
por: Shen, Hui-Xin, et al.
Publicado: (2021)

Ruxolitinib in Myelofibrosis and Polycythemia Vera
por: Wolfe, Leah
Publicado: (2016)

Thromboembolic events in polycythemia vera
por: Griesshammer, Martin, et al.
Publicado: (2019)

Genetic Background of Polycythemia Vera
por: Regimbeau, Mathilde, et al.
Publicado: (2022)

Iron deficiency in JAK2 exon12 and JAK2-V617F mutated polycythemia vera
por: Liu, Dan, et al.
Publicado: (2021)

Patterns of hydroxyurea use and clinical outcomes among patients with polycythemia vera in real-world clinical practice: a chart review
por: Parasuraman, Shreekant, et al.
Publicado: (2016)

Differential cytokine network profile in polycythemia vera and secondary polycythemia
por: Cacemiro, Maira da Costa, et al.
Publicado: (2020)

Splenectomy Normalizes Hematocrit in Murine Polycythemia Vera
por: Mo, Jan-Rung, et al.
Publicado: (2009)

Cannot write session to /tmp/vufind_sessions/sess_cs8fbs37a230clj180ggik0v0r